Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2025-04-21 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司关于举行2024年年度报告网上业绩说明会的通知
AGM Information Classification · 95% confidence The document is a notice about holding an online performance explanation meeting for the 2024 annual report. It mentions that the 2024 annual report and its summary have already been disclosed on April 22, 2025. The document invites investors to participate in the online meeting and submit questions in advance. The content is an announcement about an event related to the annual report, not the report itself. The document length is short (824 characters), and it serves as a notification for an investor presentation or meeting rather than containing financial data or the report itself. Therefore, it fits best under AGM Information (AGM-R) as it relates to an annual general meeting or similar shareholder communication event.
2025-04-21 Chinese
北京双鹭药业股份有限公司2024年度监事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2024 年度监事会工作报告' which translates to '2024 Supervisory Board Work Report' of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the supervisory board's activities, meetings, opinions on company operations, financial oversight, internal controls, and plans for the next year. It is a comprehensive report on the supervisory board's work rather than a financial report like an annual or interim report. It does not contain financial statements or earnings data but focuses on governance and supervisory activities. This fits best under the category of Board/Management Information (MANG), which includes announcements related to company board activities and management oversight. The document length is 4630 characters, which is sufficient for a detailed report but not a full financial report. Therefore, the classification is MANG with high confidence.
2025-04-21 Chinese
北京双鹭药业股份有限公司2024年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2024 年度董事会工作报告' which translates to '2024 Annual Board of Directors Work Report'. It details the activities and meetings of the board of directors throughout the year 2024, including the number of meetings held, resolutions passed, and business activities. The content focuses on the board's work and governance activities rather than financial results or audit opinions. It includes information about board meetings, decisions, and company business focus, which aligns with a Board/Management Information report. There is no indication that this is a full annual report (10-K), audit report, or other financial report. The document length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-04-21 Chinese
年度关联方资金占用专项审计报告
Regulatory Filings
2025-04-21 Chinese
独立董事自查报告
Governance Information Classification · 95% confidence The document is a self-inspection report by independent directors regarding their independence status, referencing regulatory guidelines for independent directors. It is a compliance and governance-related statement rather than a financial report or announcement of voting results. It does not contain financial data or meeting results but focuses on governance and regulatory adherence concerning board members' independence. Therefore, it fits best under Governance Information (CGR). The document length is short but contains substantive governance content, not just an announcement or certification.
2025-04-21 Chinese
年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of Beijing Shuanglu Pharmaceutical Co., Ltd. It includes information about the meeting date, agenda items, voting procedures, registration details, and proxy forms. The document does not contain the actual annual report or financial statements but rather the announcement and procedural details for the AGM. The document length is 4237 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2025-04-21 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.